This document summarizes the history and development of NovioGendix, a biotech startup focused on liquid biopsy diagnostics for urological cancers. It describes how the company was founded in 2006 by Drs. Jack Schalken and Willem Melchers based on their expertise in prostate cancer biomarker discovery and clinical validation. Key milestones included developing the PCA3 test, launching products, completing financing rounds, and building a product pipeline. In 2015, NovioGendix was acquired by MDxHealth to further commercialization of its prostate cancer diagnostic tests. The founders view this as a logical step that allows the technology to have greater impact through an established company in the urology space.